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A B S T R A C T
It is well established that the neurotransmitter norepinephrine (NE) has anticonvulsant properties.
However, NE may also have proconvulsant properties under some conditions, both in animal epilepsy
models and in humans. This paper examines the hypothesis that this neurotransmitter has
proconvulsant properties, where much of the pharmaceutical evidence comes from rodent models.
In assessing the elevated NE epilepsy hypothesis, the following seven lines of evidence are examined that
include studies of: (1) antidepressants that raise the level of NE; (2) clonidine and other alpha 2
adrenergic agonist drugs that lower the level of NE; (3) prazosin and other drugs that affect alpha
adrenoceptors; (4) propranolol and other drugs that affect beta adrenoceptors; (5) pheochromocytoma,
which is a rare cancer of the adrenal glands that can boost NE levels; (6) comorbidity of epilepsy with
bipolar disorder, hypertension, and obesity, where all four conditions may involve elevated NE; and (7)
psychological stress, which is associated with increased release of NE. The body of evidence supporting
the NE proconvulsant hypothesis is consistent with the notion that elevated, endogenous noradrenergic
transmission is an etiological factor in some cases of epilepsy.
 2010 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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A large number of studies have demonstrated that the
neurotransmitter norepinephrine (NE) has anticonvulsant proper-
ties.1 Many of these data involve rodent pharmaceutical studies of* Current address: National Institute on Alcohol Abuse and Alcoholism (NIAAA),
5625 Fishers Lane, Room 2N09, Bethesda, MD 20852-9411, USA. Tel.: +1 443 564
1306.
E-mail address: pﬁtz@mbi.mb.jhu.edu.
1059-1311/$ – see front matter  2010 British Epilepsy Association. Published by Else
doi:10.1016/j.seizure.2010.04.011epilepsy (e.g., Ref. 2), and some recent evidence includes gene
knockout studies in mice.3–6 A ketogenic diet which boosts NE can
have anticonvulsant effects in rodents,6 although boosting of NE is
not necessarily this diet’s anticonvulsant mechanism of action.7 A
series of pioneering studies in dopamine beta-hydroxylase
knockout mice (that lack NE) and alpha2a receptor knockout
mice support an anticonvulsant role for NE in these animal
models.3–5 Knockout of theNE transporter inmice, which results in
elevated levels of synaptic NE, has an anticonvulsant effect.8,9 It has
also been argued that use of antidepressants that boost NE levels
(and serotonin levels) is anticonvulsant, not proconvulsant.10vier Ltd. All rights reserved.
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vulsant at overdose levels, they may be anticonvulsant at low
doses.11
While the above studies are valid and their conclusions may
indeed be correct, there is also a signiﬁcant body of evidence that
NE is proconvulsant under certain conditions. NE is a ‘‘stress
hormone’’ in the sympathetic nervous system, where it helps
mediate the body’s ‘‘ﬁght or ﬂight’’ response. In the brain, NE is
associated with arousal and attention, where the NE boosting drug
atomoxetine is used to treat attention deﬁcit hyperactivity
disorder (ADHD).12 If NE plays an ‘‘activating’’ role in the brain,
this is consistent with it producing, under some conditions,
excessive neural activity that may characterize epilepsy. The
anticonvulsant drug valproic acid may deactivate neurons through
the inhibitory neurotransmitter, GABA.13 And the anticonvulsant
carbamazepinemay decrease the cerebrospinal ﬂuid (CSF) NE level
in persons suffering from mania.14
The rest of the paper reviews literature that supports the NE
proconvulsant hypothesis, while also presenting evidence in
support of the anticonvulsant hypothesis. These two hypotheses
are not mutually exclusive, and may each apply under different
conditions in various organisms. The focus here is on pharmaceu-
tical studies of NEmanipulation (level and receptor drug effects) in
rodent models of epilepsy. These studies, along with some human
papers, comprise the ﬁrst four lines of evidence in support of the
NE proconvulsant hypothesis. Lines ﬁve and six comprise studies of
conditions that may be characterized by elevated NE, such as
bipolar disorder and hypertension, and their potential relationship
with epilepsy. The seventh line examines the potential relationship
between psychological stress, which is associated with increased
release of NE, and epilepsy. While these lines of evidence support
the NE proconvulsant hypothesis, they in many cases also support
the NE anticonvulsant hypothesis.
2. Literature search details
This paper is based on selected keyword searches of the
Pubmed database that were conducted as recently as March 28,
2010. The following combinations of keywords were used:
(epilepsy, seizure) + (desipramine, tricyclic, reboxetine, atomox-
etine, clonidine, prazosin, propranolol, pheochromocytoma, ‘‘ce-
rebrospinal norepinephrine’’). Additional searches were made
using the terms: (epilepsy, seizure) + (comorbid, comorbidity) + (-
bipolar, hypertension, obesity, stress). Papers that were clearly
relevant to the topic were included in this review.
3. Results
3.1. Norepinephrine boosting antidepressants
A number of studies have shown that NE boosting antidepres-
sants, such as the tricyclic antidepressants and the newer drugs
reboxetine and atomoxetine, have proconvulsant and anticonvul-
sant effects, both in animal models and humans. The principal
brain mechanism of two tricyclics, desipramine and nortriptyline,
is boosting the level of extracellular NE via inhibition of the NE
reuptake transporter.15 Other tricyclic antidepressants, such as
imipramine and amitriptyline, are thought to boost signiﬁcant
amounts of both NE and serotonin,15 but in vivo these two drugs
are rapidly metabolized into desipramine and nortriptyline,
respectively.16 Rodent microdialysis studies indicate that imipra-
mine boosts brain NEmore strongly than it does serotonin.17 So the
principal brain effect of all tricyclics may be boosting of
extracellular NE.
The evidence from tricyclic epilepsy studies of rats, mice, cats,
and humans supports both the proconvulsant and anticonvulsanthypotheses. Regarding proconvulsant data, in freely moving rats,
imipramine and desipramine produced spike-wave complexes,
spikes, and increased spindling.18 A rat study testing a variety of
antidepressants found no effect on seizures after a single dose,
whereas chronic administration of these drugs was proconvul-
sant.19 In rats presenting with spontaneous petit mal-like seizures,
several tricyclics were tested and found to be proconvulsant.20 A
pharmacological study in rats concluded that the NE boosting
effects of imipramine are prominently involved in imipramine-
induced seizures.21
Regarding anticonvulsant tricyclic results from rats, in the
genetically epilepsy prone animal, several tricyclics acted as
anticonvulsants in doses substantially lower than the toxic doses
that produced spontaneous convulsions.2 In electrically kindled
hippocampal seizures, several tricyclics signiﬁcantly reduced
afterdischarge duration, with amitriptyline being the most
effective.22 A study of four tricyclics on amygdala-kindled seizures
found that only amitriptyline had an anticonvulsant effect, and
that was at near toxic doses.23
In epilepsy prone mice, desipramine potentiated the convulsant
effects of NMDA.24 Therapeutic doses of desipramine in mice were
markedly proconvulsant in amodel of lidocaine-induced seizures.25
In a mouse study which showed anticonvulsant results, amitripty-
line and imipramine provided protection against electroconvul-
sions, and they and desipramine potentiated the anticonvulsant
effect of valproate.26 In mice, the tricyclic doxepin had anticonvul-
sant activityagainstmaximal electroshock-induced seizures, aswell
as in several chemically-induced seizure models.27 A study in
anesthetized cats found that various tricyclics produced epilepti-
form pathology in neocortex, hippocampus, and brainstem.28
There are both proconvulsant and anticonvulsant results for
tricyclics in humans. In a case report of a patient whose seizures
increased in frequency during a period of severe depression,
desipramine improved both conditions.29 In contrast, another case
report indicated that a child on imipramine exhibited a seizure
disorder.30 Another case report showed that eight patients on
conventional doses of tricyclics had elevated plasma levels of the
drugs and suffered from grand mal seizures.31 In a study of 100
persons who experienced severe tricyclic antidepressant overdose,
31 had seizures during the overdose.32 A review study reported
that persons on high doses of imipraminewho had no predisposing
factors for seizures exhibited a seizure rate of approximately 0.6–
0.9%.33 Another review paper of tricyclics reported a relatively high
rate of seizures (0.4 to 1–2%) at therapeutic doses.34
Two newer drugs, reboxetine and atomoxetine, which very
speciﬁcally boost NE, may also affect epilepsy-related phenomena.
In mice, reboxetine has both proconvulsant and anticonvulsant
effects on ﬂurothyl-induced seizures.9 A study of persons with
comorbid temporal lobe epilepsy and major depression found that
treatmentwith reboxetinedidnot increase the frequencyor severity
of seizures.35 Two epidemiological studies, put forth by the
manufacturer of atomoxetine, concluded that this drug does not
increase the risk of seizures in persons being treated for attention
deﬁcit hyperactivity disorder (ADHD).36,37 In a case report, awoman
who overdosed on a very high dose of atomoxetine, presented in the
emergency room with a tonic-clonic seizure.38
As described above, NE boosting drugs can have both
proconvulsant and anticonvulsant effects in various organisms
under different experimental conditions. In rodents, more studies
showed proconvulsant effects18–21,24,25 than anticonvulsant
ones,22,23,26,27 or both effects in the same study.2,9 Human case
reports were more frequently proconvulsant30,31,38 than anticon-
vulsant,29 although perhaps there is a bias toward reporting more
proconvulsant incidents, including those related to overdoses. In
sum, these data support both the NE proconvulsant and
anticonvulsant hypotheses.
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Animal andhuman studies show that clonidine andother alpha
2 adrenergic agonist drugs can affect convulsions. These drugs
may have opposing effects on noradrenergic transmission, both
decreasing presynaptic NE release via alpha 2 autoreceptors and
activating postsynaptic alpha 2 receptors.39 Because of this, these
drugsmay decrease noradrenergic transmission by decreasing NE
release, or increase such transmission by acting as a postsynaptic
agonist. These two possibilities will be addressed further in
Section 4.
There are both proconvulsant and anticonvulsant results for
clonidine in the rat. In a study of audiogenic seizures, clonidine at
high doses was anticonvulsant, whereas at low doses (which are
thought to be more presynaptic) it was proconvulsant.40 In rats
implanted with chronic electrodes, clonidine and the alpha 2
agonist guanfacine prolonged EEG paroxysms, as did the alpha 1
antagonist drug, prazosin.41 For quinolinic acid-induced convul-
sions, clonidine was proconvulsant at low doses and anticonvul-
sant at higher doses.42
For allylglycine-induced seizures in the rat, clonidine had an
anticonvulsant effect.43 That result, coupled with an anticonvul-
sant effect of prazosin in the same study, led the authors to
conclude that decreased noradrenergic transmission has an
anticonvulsant effect in this animal model.43 In another study,
clonidine and four other alpha 2 agonists had an anticonvulsant
effect on pentylenetetrazol (PTZ)-induced convulsions.44 Another
ﬁnding is that a subthreshold dose of clonidine, when combined
with the drug di-n-propylacetate (DPA), had an anticonvulsant
effect on PTZ-induced convulsions.45 In a hippocampal slice
preparation, clonidine and other alpha receptor agonists were
anticonvulsant, whereas various beta receptor agonists were
proconvulsant.46 Depletion of NE with the drug AMPT potentiated
kainic acid-induced epileptic symptoms, and the effect was
antagonized by clonidine.47
In the quakingmousemodel of epilepsy, clonidine and prazosin
had a proconvulsant effect on handling-induced convulsions.48
Regarding anticonvulsant effects of clonidine in themouse, a study
of this drug and two other alpha 2 agonists found that these drugs
reduce the severity of audiogenic seizures.49 In another study,
clonidine had an anticonvulsant effect on metaldehyde-induced
seizures.50 Clonidine protected against imipramine-induced sei-
zures, as did prazosin and AMPT, suggesting that decreasing
noradrenergic transmission is anticonvulsant in this animal
model.51 In a related study, a number of noradrenergic drugs
modulated strychnine-induced seizures, with clonidine being
anticonvulsant, and the authors conclude that increasing norad-
renergic transmission is proconvulsant here.52
There do not appear to be many studies of the effects of
clonidine on human epilepsy. In a study of 14 epileptic patients,
premedication with clonidine increased focal epileptic discharges
in nine, as measured with magnetoencephalography (MEG).53 In
another MEG study of epileptic patients, about 67% showed
increased spike activity with clonidine administration.54
The above data show both proconvulsant and anticonvulsant
effects for clonidine and other alpha 2 agonists in animal models.
In rodents, fewer alpha 2 agonist studies showed proconvulsant
effects41,48 than anticonvulsant effects,43–47,49–52 and some
showed both,40,42 which may depend on dose. Two human
studies showed proconvulsant effects.53,54 As mentioned above,
clonidine and other alpha 2 agonists may either be increasing or
decreasing noradrenergic transmission, so these data do not
strongly indicate whether NE is proconvulsant or anticonvulsant,
but at least suggest that NE affects convulsions andmay have both
proconvulsant and anticonvulsant properties under various
conditions.3.3. Prazosin and other alpha receptor studies
Studies of the alpha 1 antagonist drug, prazosin, related drugs,
and binding studies of the alpha 1 receptor indicate a role for this
receptor in epilepsy. In a study of anesthetized rats, prazosin
blocked the suppression of penicillin-induced focal epileptiform
activity produced by locus coeruleus stimulation.55 In other words,
prazosin was proconvulsant in this model.55 In a mouse model of
electroshock seizures, the alpha 1 agonist St 587 and the beta
agonist isoprenaline were both proconvulsant.56 In another study,
St 587 had no effects on the thresholds for electroshock and PTZ-
induced seizures in mice and rats, but was anticonvulsant in
kindled rats and epileptic gerbils.57 A binding study revealed that
there may be fewer alpha 1 recognition sites in the genetically
epilepsy prone rat.58 The age related susceptibility of the DBA/2J
strain of mice to audiogenic seizures may be related to a reduced
number of alpha 1 binding sites, rather than to alpha 2 or beta
adrenoceptor binding sites.59 Transgenicmice that overexpress the
alpha 1b receptor exhibit increased in vivo spontaneous interictal
epileptogenicity and EEG/behavioral seizures.60 Moreover, alpha
1b knockout mice are markedly resistant to chemoconvulsants.61
In human patients with epilepsy, there is reduced alpha 1 receptor
density, as measured by labeled prazosin binding, at sites in
epileptic foci.62
The above rodent data on prazosin show a proconvulsant
effect,55 whereas the alpha 1 agonist St 587 was proconvulsant in
one study56 and anticonvulsant in another.57 These data suggest
both proconvulsant and anticonvulsant affects for NE. The alpha 1
receptor data do not strongly suggest whether NE is proconvulsant
or anticonvulsant, as reductions in receptor density are associated
with convulsions58,59 or protection against convulsions,61 whereas
overexpression is proconvulsant.60
3.4. Propranolol and other beta receptor drug studies
Propranolol is a non-selective beta adrenoceptor antagonist
drug, meaning it blocks both beta 1 and beta 2 receptors, and it
appears to affect epilepsy. In the rat, propranolol blocked the
reduction of penicillin-induced hippocampal spiking produced by
locus coeruleus stimulation.63 In other words, propranolol was
proconvulsant in this model.63 Regarding anticonvulsant results in
the rat, intracerebroventricular administration of propranolol and
another beta blocker, timolol, was anticonvulsant in a PTZ-induced
model of convulsions.64 In the same study, various beta 1
antagonists were only weakly anticonvulsant, leading the authors
to conclude that deactivation of beta 2 receptors is anticonvul-
sant.64 Pretreatment with propranolol inhibited isoniazid-induced
convulsions in a dose dependent manner.65 In a study of lidocaine-
induced convulsions in awake rats, propranolol increased seizure
thresholds.66
In the mouse, propranolol (and reserpine) reduced latency for
PTZ-induced seizures.67 Propranolol also antagonized strychnine-
induced seizures.68 Audiogenic seizure prone DBA/2 mice had
increased density ofmidbrain beta adrenergic receptors, compared
with seizure resistant C57BL/6 mice.69 In the same study,
propranolol attenuated all stages of seizure syndrome.69 Propran-
olol and the beta blocker pindolol exhibited signiﬁcant protective
effects againstmaximal electroshock seizures.70 Propranolol alone,
and in combination with the drug nifedipine, produced an
anticonvulsant effect onmaximal electroshock-induced seizures.71
Propranolol was also anticonvulsant in audiogenic, tonic-clonic
seizures in DBA/2 mice.72 This drug and its two enantiomers dose
dependently raised the threshold for tonic electroshock seizures.73
Regarding human results with this drug: in two infants with
involuntary movements of polymyoclonia and opsoclonus, pro-
pranolol produced marked improvement in both children.74 In 12
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with propranolol produced a signiﬁcant reduction in epileptic
manifestations.75
In the above rodent data, propranolol more frequently had
anticonvulsant properties64–66,68–73 than proconvulsant ones,63,67
suggesting a proconvulsant role for NE since propranolol blocks
noradrenergic transmission. Two human studies also support the
NE proconvulsant hypothesis, since propranolol was anticonvul-
sant in these studies.74,75
An additional point of evidence regarding a proconvulsant role
for NE in rodents comprises the mutant ‘‘tottering’’ mouse.76 This
mouse has hyperinnervation of various brain structures (such as
hippocampus and cerebellum) by axons of the locus coeruleus, and
concomitant elevated levels of NE in these structures, while
exhibiting spontaneous spike-wave and focal motor seizures.76
Besides the NE increase in these mice, other pharmacological
parameters are normal, such as tyrosine hydroxylase activity, NE
turnover, serotonin content, and choline acetyltransferase activi-
ty.77 The proconvulsant phenotype of these mice can be mitigated
by selective lesions of central noradrenergic axons early in
development.78
3.5. Pheochromocytoma
Pheochromocytoma is a rare cancer of the adrenal glands that
can boost NE levels systemically. Hypertension, which is often
present in pheochromocytoma, may make the blood–brain barrier
permeable to NE, thereby allowing NE released by the adrenal
glands to penetrate the brain.79 There are several reports of this
cancer being proconvulsant. A patient with complex partial
seizures had a cluster of symptoms suggestive of pheochromocy-
toma.80 A child with a malignant form of pheochromocytoma
showed central nervous system symptoms imitating epilepsy.81 In
another case report, a child presented with seizures and a
hypertensive crisis, and was found to have multiple extra-adrenal
pheochromocytomas.82 A young man developed seizures along
with hypertension and other symptoms; he was diagnosed with
pheochromocytoma and adrenalectomy resulted in complete
recovery.83 These data support the NE proconvulsant hypothesis.
3.6. Bipolar disorder, hypertension, and obesity
Evidence that NE is elevated in persons with bipolar disorder
dates back to the catecholamine hypothesis of mood disorders, put
forth by the late Schildkraut.84 There is also blood measure
evidence that brain NE is elevated during periods of mania or
hypomania,85 where changes in plasma MHPG (an NE metabolite)
may reﬂect changes in central NE. The rate of both unipolar
depression and bipolar disorder in people with epilepsy appears to
be higher than in the general population.86 In a survey of 127,800
adults in the United States, bipolar symptoms were present in
12.2% of persons with epilepsy, and the two illnesses were more
frequently comorbid than bipolar disorder was with migraine
headaches, asthma, or diabetes mellitus.87 Bipolar disorder was
also 6.6 times more common in persons with epilepsy than in
healthy subjects.87 In a study of 143 adult outpatients with
epilepsy, 11.8% had bipolar disorder as well.88 In another study of
117 adult outpatients, 14.5% met DSM-IV criteria for having manic
or hypomanic episodes.89 There is a case report of a patient who
presented with bipolar mania and photoconvulsive epilepsy, who
was treated successfully with carbamazepine.90 Epilepsy and
bipolar disorder may also share biochemical and pathophysiologi-
cal commonalities, including kindling.91 In patients with comorbid
bipolar disorder and epilepsy, anticonvulsants often treat both
disorders simultaneously.92 In general, anticonvulsants are com-
monly used to treat bipolar disorder.93 The above data on bipolardisorder are consistent with the NE proconvulsant hypothesis,
without supporting the anticonvulsant hypothesis.
Persons with hypertension may in some cases have elevated
levels of plasma NE,94 and drugs that lower NE, such as clonidine,
reduce bloodpressure.95 There is evidence that bothplasma andCSF
NE are elevated in hypertensives compared to normotensives.96,97
Even persons with borderline hypertension may have elevated
plasma and CSF NE.98 In a case–control study of subjects 55 years or
older, severe uncontrolled hypertension increased the risk of
unprovoked seizures.99 In a large case–control study, a variety of
vascular determinants, including hypertension, were associated
with lifetime epilepsy and late-onset epilepsy.100 These data on
hypertension are consistent with the NE proconvulsant hypothesis.
In humans, excessive body weight is associated with adreno-
ceptor polymorphisms and elevated blood NE.101 A strain of
genetically obese mice (called OBOB) has higher levels of
hypothalamic and telencephalic NE than lean littermates.102,103
In rats, chronic infusion of NE into the ventromedial hypothalamus
induces obesity.104 These data suggest that there is elevated
central NE in some cases of obesity. There are high rates of obesity
in persons with epilepsy, with one study of 8057 adults reporting a
34.1% rate of obesity, versus a 23.7% rate in persons without
epilepsy.105 Childrenwith newly diagnosed untreated epilepsy had
higher bodymass index compared to healthy controls; 38.6% of the
epilepsy cohort were overweight or obese.106 Another study
reports that poor ﬁtness and obesity are common in persons with
epilepsy.107 However, teens with epilepsy may simply participate
in fewer sports activities than controls, so lack of exercise may
result in them being overweight.108 These data on obesity are
consistent with the NE proconvulsant hypothesis.
3.7. Psychological stress
Psychological stressors can producemarked release of NE in the
bloodstream (and the brain) as part of the body’s sympathetic
‘‘ﬁght or ﬂight’’ response. Psychological stress can have an
anticonvulsant effect, which has been demonstrated in mice109
and rats.110 A study of persons with epilepsy who were evacuees
from a natural disaster, versus control personswith epilepsy, found
that this stressor produced a small increase in the number of
seizures.111 A related point is that having seizures is itself stressful,
and this may lead to various pathophysiological changes that
trigger physical illnesses,112 which may feed back on the epilepsy
itself. These data support both the NE proconvulsant and
anticonvulsant hypotheses.
An additional line of evidence that is potentially relevant to the
NE proconvulsant hypothesis comprises data directly relating CSF
NE with convulsions. As noted above, a caveat is that having
epilepsy is stressful for persons, and this stressor may feedback on
the NE system and thereby increase NE levels.112,113 A second
caveat is that the process of measuring CSF NE levels, typically
through a spinal tap, is a potentially stressful surgical procedure
that may also feedback on the NE system and increase NE levels. A
study of 15 personswith epilepsy and 75 controls found higher CSF
levels of NE in epileptics.114 However, another study found similar
CSF concentration of the NE metabolite, MHPG, between persons
with partial complex seizures and neurologic controls.115 Follow-
ing secondarily generalized tonic-clonic seizures, CSF NE concen-
tration was signiﬁcantly higher than interictal concentration,116
suggesting that NEmay either increase before or just after seizures.
4. Discussion
The evidence reviewed in this paper supports the hypothesis
that NE is proconvulsant under some conditions. Much of the
evidence also supports the more well-established hypothesis that
Table 1
Summary of data. The presence or absence of one ormore studies cited in this review that supports the given question is noted by a ‘‘Yes’’ or ‘‘No’’. This table only includes data
for the given classes of drugs themselves, rather than related receptor studies noted in the text. The evidence for alpha 2 agonists is inconclusive because they may either be
increasing or decreasing noradrenergic transmission.
Proconvulsant Anticonvulsant Supports NE proconvulsant hypothesis Supports NE anticonvulsant hypothesis
NE boosting antidepressants Yes Yes Yes Yes
Alpha 2 agonists Yes Yes ? ?
Alpha 1 antagonists Yes Yes Yes Yes
Beta blockers Yes Yes Yes Yes
Pheochromocytoma Yes No Yes No
Bipolar disorder Yes No Yes No
Hypertension Yes No Yes No
Obesity Yes No Yes No
Psychological stress Yes Yes Yes Yes
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brief discussion of the implications of the reviewed data, and a few
ideas related to NE and epilepsy.
The tricyclic antidepressant studies, as well as studies of
reboxetine and atomoxetine, may provide a direct test of NE
convulsive hypotheses since these drugs appear to principally
boost NE.15–17 Many of the reviewed tricyclic studies indeed
support the NE proconvulsant hypothesis, both in animals and
humans. Studies of the drug clonidine and other alpha 2 adrenergic
agonists provide a far less direct test of the proconvulsant
hypothesis, since these drugs may both decrease presynaptic
release of NE and stimulate postsynaptic alpha 2 receptors, and the
relative importance of the two potentially opposing effects may
differ in various animal models and in humans. Ref. 5 appears to
resolve the controversy inmice, where clonidine is reported have a
proconvulsant effect based on a decrease in autoreceptor-
mediated release of NE. Nonetheless, the safe conclusion from
the clonidine data is that NE has convulsive effects, butwhether NE
is proconvulsant or anticonvulsant in all species may not be
resolved by these data. On the other hand, when the clonidine data
are combined with data from other noradrenergic drugs (such as
prazosin) in the same study,41,43,51 these data can shed light on the
convulsive hypotheses, since the other drugs may reveal which of
clonidine’s twomechanisms is more prominent in the given study.
The prazosin and propranolol data provide amore direct test of the
NE convulsive hypotheses, since these drugs block noradrenergic
transmission through particular adrenoceptors. Many of the
results for these two drugs are anticonvulsant, which when
combined with the tricyclic data, strengthen the NE proconvulsant
hypothesis. It should be noted that in cases where NE may be
proconvulsant, the effect need not be mediated through all
subtypes of adrenoceptors. In otherwords, some receptor subtypes
could still be anticonvulsant when activated by NE or a drug.
The results for pheochromocytoma being associated with
seizures are interesting but caution should be noted since these
are case reports. The association of bipolar disorder, hypertension,
and obesity with epilepsy is also promising for the NE procon-
vulsant hypothesis. However, the interpretation of these results,
for hypertension and obesity (and pheochromocytoma), is depen-
dent onwhether NE is elevated in the brain under these conditions.
Elevated blood NE may result in elevated brain NE,79 although this
is not necessarily the case. Pheochromocytoma, bipolar disorder,
hypertension, and obesity may be associated with other phenom-
ena that increase the rate of epilepsy, but increased NE is one of
these candidate phenomena. The potential relationship between
psychological stress and epilepsy merits further investigation.
It appears that NE has general proconvulsant properties that are
not speciﬁc to a particular type of epilepsy, brain region,
convulsant agent, treatment duration, or species. For each of
these ﬁve entities there are examples of NE’s non-speciﬁcity. For
example, regarding type of epilepsy, several tricyclics enhanced
spontaneous absence-like seizures in rats,20 whereas propranololwas anticonvulsant in audiogenic, tonic-clonic seizures in DBA/2
mice.72 The above studies also showed proconvulsant effects of NE
on different brain regions. For example, a study in anesthetized
cats found that various tricyclics produced epileptiform pathology
in neocortex, hippocampus, and brainstem.28 In addition, a large
number of the above studies showed that the proconvulsant effects
of NE are not limited to a particular convulsant agent (e.g.,
lidocaine or PTZ). For example, therapeutic doses of desipramine in
mice were proconvulsant in a model of lidocaine-induced
seizures,25 and propranolol and another beta blocker, timolol,
were anticonvulsant in a PTZ-induced model of convulsions.64 In
addition, the proconvulsant properties of NE were evident both
upon acute28 and chronic19 drug administration. Finally, procon-
vulsant results for NE were present in a number of species
described in this paper, includingmice, rats, cats, and humans. This
body of evidence is consistent with the hypothesis that NE has
general proconvulsant properties.
The mechanism of action by which NE may achieve its
proconvulsant effects, or its anticonvulsant ones, remains unclear.
Since adrenoceptors are G protein-coupled receptors that produce
changes in intracellular second messenger processes, such as the
level of cyclic AMP (cAMP), as a result of binding to NE, one avenue
of inquiry into the convulsive effects of NE would be pharmaco-
logical or genetic manipulation of relevant second messenger
processes in brain slice preparations. One possibility is that NE
produces increases in cellular membrane potential as a result of
binding to its receptors, consistent with the idea that NE increases
general excitability of neurons. However, this hypothesis would
not necessarily predict that all neurons in noradrenergic circuits
should be excited by NE, since inhibitory interneurons might show
decreases in membrane potential. Another possibility is that NE
has no direct effects on convulsions through changes in membrane
potential, but instead some other second messenger process
facilitates convulsions originating in those neurons. A third
possibility is that NE has no direct effect on convulsions through
membrane potential or other second messenger processes in
neurons bearing adrenoceptors, but instead these cells participate
in circuits that facilitate convulsions in non-adrenergic receptor
bearing cells.
How might one go about testing the NE proconvulsant
hypothesis itself, to a greater degree than it has already been
tested? As reviewed in this paper, there is already a large body of
evidence in support of the hypothesis. However, continued inquiry
into the hypothesis may not only better establish its validity, but
also provide more information about the circumstances in which
NE plays a proconvulsant role. Since noradrenergic drugs are not
considered a ﬁrst-line treatment for epilepsy in most persons,
perhaps double blind, placebo controlled studies could be
undertaken that add noradrenergic drugs, such as desipramine,
clonidine, or propranolol, onto existing anticonvulsant drug
regimens. Epidemiological studies of seizure rates in large
numbers of persons who have taken noradrenergic drugs
P.J. Fitzgerald / Seizure 19 (2010) 311–318316(especially when these are the only drugs being taken), including
data on persons with no history of seizures, would also shed
further light on the hypothesis.33,34 Regarding animal models,
perhapsmore electrophysiological studies could be conducted that
apply NE directly to brain slices and measure effects on
convulsions, which would constitute a more direct test of the
hypothesis than administration of drugs that manipulate NE or its
receptors, since these drugs may have additional effects on other
neurotransmitter systems or cellular processes. Alteration of
noradrenergic genes in mice, including both knock-in and
knockout manipulations, would also provide additional testing
of the NE convulsive hypotheses, especially as we come to
understand murine noradrenergic genes in greater detail.3–5,61
Regarding the potentially proconvulsant role of NE in some
cases of epilepsy, an analogy can be drawn with the ﬁeld of
pharmaceutical drug treatment of asthma. Long acting beta agonist
(LABA) drugs, which activate beta adrenoceptors, have been a
standard anti-inﬂammatory treatment of asthma for many years.
However, a recent seminal paper in that ﬁeld117 showed that one
LABA, salmeterol, can actually increase respiratory-related mor-
tality. Perhaps a similar situation exists for epilepsy, wherein
increasing noradrenergic transmission may in some cases be
beneﬁcial, but may also in certain situations be harmful (though
not necessarily lethal).
One concept that may unify the NE proconvulsant and
anticonvulsant hypotheses is that perhaps either too high or too
low an extracellular concentration of this neurotransmitter is
proconvulsant. In other words, a mid-range brain concentration of
NEmay be most healthy. For example, when raising the level of NE
with a tricyclic antidepressant is proconvulsant in a given animal
or human, perhaps the endogenous level of NE was already at a
mid-range value. Or, when raising NE with a tricyclic is
anticonvulsant, perhaps the endogenous level of NE was too
low. A related idea is that changes in the concentration of NE,
induced by pharmaceutical drugs for example, may have
proconvulsant or anticonvulsant effects under different conditions
in various organisms. If NE is indeed proconvulsant in some cases
of epilepsy, treatment with noradrenergic transmission decreasing
pharmaceutical drugs, such as propranolol and perhaps clonidine,
may be indicated in those cases.
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